Sun Pharma touched a high of Rs 1,459 and finally ended at Rs 1,436, up 2% from the previous close. The counter clocked volumes of 234,664 shares on the NSE today.
Cadila Healthcare erased all its losses and soared to a high of Rs 590. The scrip finally ended at Rs 589, up 3% from its previous close. The counter witnessed trades of 70,167 shares on the NSE.
_________________________________________
(Updated at 1040hrs)
Sun Pharma has gained after the Madras High Court has stopped Zydus Cadila (Cadila Healthcare) from selling anti-depressant drug, Venz (venlafaxine), in the domestic market for the time being, on the basis of the trademark complain lodged by the company.
The stock opened at Rs 1,407 and soared to a high of Rs 1,423. The stock is now trading at Rs 1,422, up 1.5% from the previous close. The counter has clocked volumes of 4,058 shares on the BSE.
Cadila Healthcare opened at Rs 560 and slipped to a low of Rs 557, down 2% from the previous close. The stock has however recoverd and is now at flat at Rs 570. The counter has clocked volumes of 1,428 shares on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
